References
  1. Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, Yusuf S. Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res. 2017 Sep 1;121(6):695-710.
  2. Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - A concise summary. Vascul Pharmacol. 2019 Feb;113:1-8.
  3. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309(07):396–403.
  4. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985;313(22):1369–1375.
  5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2(8607):349–360.
  6. Piepoli MF, Hoes AW, Agewall S, et al; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37(29):2315–2381.
  7. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019 January. 2018:S86-S104
  8. Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016; 164: 836-45.
  9. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74(10):1376–1414.
  10. McNeil JJ, Nelson MR, Woods RL, et al; ASPREE Investigator Group. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018;379(16):1519–1528.
  11. Gaziano JM, Brotons C, Coppolecchia R, et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392(10152):1036–1046.
  12. Bowman L, Mafham M, Wallendszus K, et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379(16): 1529–1539.
  13. Oğuzhan Çelik Cem ÇilBülent Özlek , et al. Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study. Anatol J Cardiol. 2018 Dec;20(6):354-362.
  14. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-S73.
  15. Shah RR, Pillai A, Omar A, Zhao J et al. Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement. Catheter Cardiovasc Interv 2017; 89: E99-E103.
  16. Alan P Jacobsen, Inbar Raber, Cian P McCarthy et al. Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted? Circulation. 2020 Oct 20;142(16):1579-1590. doi: 10.1161/CIRCULATIONAHA.120.045695.
  17. Salih Kılıç, Ahmet Çelik, Elif Çekirdekçi, et al. The Prevalence and Risks of Inappropriate Combination of Aspirin and Warfarin in Clinical Practice: Results From WARFARIN-TR Study. Balkan Med J. 2019 1;36(1):17-22.
  18. Manes C, Giacci L, Sciartilli A, D’Alleva A, De Caterina R. Aspirin overprescription in primary cardiovascular prevention. Thromb Res. 2006;118:471–477.
  19. Jeffrey J VanWormer, Aaron W Miller, Shereif H Rezkalla. Aspirin overutilization for the primary prevention of cardiovascular disease. Clin Epidemiol . 2014 Dec 1;6:433-40.
  20. Ravi S Hira , Kevin Kennedy , Vijay Nambi , et al . Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20;65(2):111-21.
  21. Colin W O’Brien, Stephen P Juraschek,  Christina C Wee. Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey. Ann Intern Med. 2019 Oct 15;171(8):596-598. doi: 10.7326/M19-0953. Epub 2019 Jul 23.